Table 1 Clinical characteristics of 203 patients with chronic hepatitis B with nucleos(t) ide analogue-induced HBeAg seroclearance

Cohort number (n)

203

Male: Female (%)

Mean age at baseline, year (range)

37 (18–82)

Mean age at HBeAg seroclearance, year (range)

40 (20–84)

Mean age at last follow-up, year (range)

44 (24–85)

Follow-up duration, year (range)

5 (2–11)

First-line antiviral therapy (%)

173 (85.2)

Entecavir: Tenofovir: Entecavir plus Tenofovir (%)

152:49:2 (74.9:24.1:1.0)

 Liver cirrhosis (%)

75 (36.9)

 Diabetes (%)

33 (16.3)

 Mean HBV DNA^†, log₁₀ IU/mL (range)

1.3 (negative-4.9)

 Mean ALT^*, IU/L (range)

25 (14–110)

 Mean albumin, g/dL (range)

4.2 (3.0–5.1)

 Mean bilirubin, mg/dL (range)

1.0 (0.8–2.5)

 Mean platelet count, 10³/μL (range)

183 (130–427)